euro adhoc: Sartorius AG / other / Currency-adjusted sales revenue up 3.8% | EBITA margin at 8.9% | Increase in sales revenue and profitability forecasted for the second half

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Preliminary Figures for the First Half of 2008

28.07.2008

To ensure the best possible comparability, the figures of the
year-earlier period are presented on a pro forma basis and adjusted
for non-operating effects ("underlying").

In the first half of the current financial year, the Sartorius Group
achieved currency-adjusted growth in sales revenue of 3.8%. At
current exchange rates, sales revenue is at EUR304.0 million and thus
at the previous year´s level (EUR304.8 mn; -0.2%). For the
Biotechnology Division, the temporarily quite challenging US market
environment played a significant role. Therefore, currency-adjusted
global sales revenue rose a comparably low 2.8%. In the reporting
currency, the division´s revenue at EUR184.1 mn is 1.3% lower than
the year-earlier figure (EUR186.6 mn). The Mechatronics Division
increased its currency-adjusted sales revenue by 5.5% (current
exchange rates: +1.5%) to EUR119.9 mn (2007: EUR118.2 mn).

On the basis of constant currencies, Group order intake attained
approximately the same level of the strong first half in 2007
(+0.1%). In the reporting currency, order intake is at EUR311.3 mn
(2007: EUR324.0 mn). This corresponds to a decrease of 3.9%
(Biotechnology: -5.6%, currency-adjusted: -1.6%; Mechatronics: -1.2%,
currency-adjusted: +2.7%) and can be primarily attributed to
fluctuations in the Biotechnology Division´s project business.

Operating earnings (EBITA) were EUR27.0 mn (2007: EUR28.9 mn); the
Group´s EBITA margin was 8.9% (2007: 9.5%). EBITA of the
Biotechnology Division declined from EUR21.3 mn to EUR20.4 mn
(margin: down from 11.4% to 11.1%) and that of the Mechatronics
Division from EUR7.7 mn to EUR6.6 mn (margin: down from 6.5% to
5.5%). On the basis of the previous year´s exchange rates, the EBITA
margin for both divisions and the group is approximately one
percentage point higher than in current exchange rates.

Consolidated net profit after minority interest was likewise impacted
by the less favorable exchange rates and by the higher euro base
interest rate, and is at EUR7.3 mn (2007: EUR9.7 mn). Earnings per
share, excluding the two non-cash items of amortization and interest
for the share price warrants granted, were EUR0.57 (2007: EUR0.67).

In the second half, we expect that sales revenue for both divisions
will be above the first-half level. For the Biotechnology Division,
we forecast a higher growth rate than in first half, whereas for the
Mechatronics Division, we project that slower economic activity will
slightly dampen its pace of growth. For both divisions, profitability
should be higher in the second half than in the first. However, we do
not expect to reach our ambitious full-year targets. Because of the
present uncertainties concerning the US biotechnology market and the
global economic climate, a more precise quantitative forecast is
currently not possible.

in millions of EUR 1st half 2008 1st half 2007 Change
(unless otherwise specified) pro forma in %

Sartorius Group
Sales revenue 304.0 304.8 -0.2 (+3.8)
Order intake 311.3 324.0 -3.9 (+0.1)
EBITA 1) 27.0 28.9
Net profit for the period 1) 7.3 9.7
Earnings per share 1)2) in EUR 0.57 0.67

Biotechnology Division
Sales revenue 184.1 186.6 -1.3 (+2.8)
Order intake 187.1 198.3 -5.6 (-1.6)
EBITA 1) 20.4 21.3

Mechatronics Division
Sales revenue 119.9 118.2 +1.5 (+5.5)
Order intake 124.1 125.6 -1.2 (+2.7)
EBITA 1) 6.6 7.7

in parentheses: currency-adjusted 1) underlying for 2007 2) excluding
non-cash amortization and, for 2008, additionally excluding non-cash
interest expenses for share price warrants

Dr. Joachim Kreuzburg, CEO of Sartorius, will discuss the first-half
results for Sartorius with analysts and investors in a teleconference
on June 29, 2008, at 3:30 p.m. CET. You may dial into this
teleconference starting at 3:15 p.m. CET at the following numbers:

Germany: +49 (0)69 5007 1317
France: +33 (0)1 70 99 43 03
UK: +44 (0)20 7806 1966
USA: +1 718 354 1390

The dial-in code is 4161181.

To view the webcast, log onto http://www.sartorius.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Andreas Wiederhold

Treasury & Investor Relations

Telefon: +49 (0)551 308-1668

E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade